SIGA Technologies, Inc. (SIGA) is a Healthcare stock trading at $3.05 (as of 2026-08-21), with a market capitalization of $218.76M and a trailing P/E of 10.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on infectious disease and health security in the United States. Its lead product, TPOXX, is an oral antiviral formulation for treating human smallpox caused by variola virus, and it also participates in a partnership with Cipla Therapeutics for antibacterial drugs primarily addressing biothreats.
SIGA Technologies sells biothreat treatments, led by TPOXX (oral tecovirimat), and it earns revenue mainly from U.S. government procurement and deliveries to the Strategic National Stockpile and other government customers, with additional revenue lines such as EGIS and DIGA.
SIGA's profit model is structurally tied to government contract procurement remaining under existing Tecovirimat arrangements, and to whether those arrangements translate into delivered shipments to U.S. agencies like the Strategic National Stockpile.
| Tecovirimat Remaining Procurements | $0.5B |
| Oral to SNS | $0.1B |
| IV to SNS | $0.0B |
| IV to US Govt | $0.0B |
| EGIS | $0.0B |
| 19C BARDA First IV Sales | $0.0B |
| DIGA | $0.0B |
| Oral to DOD | $0.0B |
| International Oral | $0.0B |
Business quality (Weak): Clear operating focus on Tecovirimat contract procurement and delivery, but financial performance is still characterized by a very weak operating margin in the latest quarter, suggesting costs can outweigh gross profit and timing of government-related revenue matters.
Valuation: At 14× earnings, SIGA trades 17% below the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.
| Price | $3.05 |
| Market Cap | $218.76M |
| P/E Ratio | 10.8 |
| EV / EBITDA | 3.5 |
| Price / Book | 1.44 |
| Price / Sales | 2.33 |
| DCF Value (model) | $7.36 |
| DCF Upside vs Price | 141.3% |
| Revenue (TTM) | $94.57M |
| Net Margin | 24.6% |
| Revenue Growth (YoY) | -11.3% |
| EPS Growth (YoY) | 400.0% |
| Altman Z-Score | 7.93 (safe) |
| Stock P/E | 10.8 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
| vs Sector | -50.1% |
| vs Industry | -36.2% |
| Top Institutional Holder | BlackRock, Inc. ($18.69M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Diem Nguyen |
| Employees | 46 |
| Country | US |
| IPO Date | 1997-09-10 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.